CanSino Biologics (06185) has issued an announcement that the company's A-shares experienced abnormal trading fluctuations, with the cumulative deviation of daily closing price gains exceeding 30% over three consecutive trading days on September 28, September 29, and September 30, 2026, in accordance with the relevant provisions of the Shanghai Stock Exchange Trading Rules and the Shanghai Stock Exchange Science and Technology Innovation Board Real-Time Monitoring Rules for Abnormal Trading.

Following a self-examination, the company confirmed that its current production and operations are normal, and its internal operational order remains normal, while the market environment and industry policies in which the company operates have not undergone major adjustments. The company conducted a self-review and sent letters to its controlling shareholder and actual controller for verification.

As of the disclosure date of this announcement, the company's controlling shareholder and actual controller have no undisclosed material matters that should be disclosed, other than information already publicly disclosed on designated information disclosure media, including but not limited to major matters under planning such as mergers and acquisitions, share issuance, debt restructuring, business restructuring, asset divestiture, and asset injection.

The company has noted recent market attention to the development of mRNA technology, as well as the release or planned public disclosure of phased clinical data for overseas mRNA tumor vaccines. The mRNA platform is one of the technology platforms in which the company is invested, and the company is currently developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In terms of therapeutic areas, the company is advancing research and development of mRNA vaccines for indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of In Vivo CAR-related therapies, all of which are currently at an early stage.

Upon verification, the company has not found any other major events that could potentially have a significant impact on its stock price. During the period of this abnormal stock trading fluctuation, the company's directors, senior management, controlling shareholder, and its concerted parties did not buy or sell the company's shares.